Warm Autoimmune Hemolytic Anemia with Chronic Hepatitis B

Authors

  • Adefri Wahyudi Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Indonesia, 25163
  • Fadrian Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Indonesia, 25163
  • Rudy Afriant Division of Medical Hemato-oncology, Department of Internal Medicine, Faculty of Medicine, Andalas University, Indonesia, 25163

DOI:

https://doi.org/10.32734/sumej.v7i1.11836

Keywords:

Chronic Hepatitis B, Steroid, Warm AIHA

Abstract

Warm autoimmune hemolytic anemia (wAIHA) is caused by erithrocytes destruction by IgG or IgG plus C3d-mediated autoantibody. Long use steroids are first line therapy of wAIHA. It  has risk infection reactivation, like chronic hepatitis B.  Man, 64 y.o, hospitalized with diagnosis wAIHA and chronic hepatitis B. Diagnosis of wAIHA is built by: severe normocytic normochromic anemia, reticulocytosis 42.29%, increasing lactate dehydrogenase 397 U/L, direct Coombs test (+4), antibody screening IgG (+4). Anothers laboratorium findings: HbsAg (+), albumin 3.5 g/dL, ALT U/L, rapid HIV (-), anti HCV (-). There is no blast found in peripheral blood and bone marrow smear. Patient also diagnosed chronic hepatitis B inactive phase with negative HbeAg, HBV DNA 547 IU/L, normal liver finding in abdominal USG and moderate fibrosis from fibroscan. Washed red cell transfussion was administered, 2 x 125 mg methilprednisolone iv (3 days) tapering off until to 40 mg/day doses. He did not get antiviral prophylaxis and be planned to reevaluate in next 6 months.  Steroid is first line therapy in wAIHA. When wAIHA is diagnosed, determination of chronic hepatitis B status should confirmed.  There is a risk of reactivation of chronic hepatitis B infection so monitoring is needed.

Downloads

Download data is not yet available.

References

Parjono E. et al (eds). Buku Ajar Ilmu Penyakit Dalam Volume VII. Jakarta: Interna Publishing. 2018;663–8.

Barcellini W, Zaninoni A, Giannotta A, et al. Review: New insights in autoimmune hemolytic anemia: from pathogenesis to therapy. Journal of Clinical Medicine. 2022;3859(9):1–19

Hill A, and Hill QA. Autoimmune hemoliytic anemia. Hemolytic Anemia: Cornucopia of causes. American Society of Hematology. 2018:382–9

Parjono E, et al (eds). Buku Ajar Ilmu Penyakit Dalam Volume VII. Jakarta: Interna Publishing. 2018;632–5

Zanella A, and Barcellini W. Review: Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–54

Perhimpunan Peneliti Hati Indonesia. Konsensus Nasional Penatalaksanaan Hepatitis B. Jakarta: Perhati. 2018.

Hatano M, Mimura T, Shimada A, et al. Original article: Hepatitis B virus reactivation with corticosteroid therapy in patiens with adrenal insuficiency. Endocrinology, Diabetes & Metabolism. 2019;2:1–7.

Zhong Z, Liao W, Dai L, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Annals of the Rheumatic Diseases. 2022;81:584–91.

Jeong W, Choe JY, Song BC, et al. Effect of low dose corticosteroid use on HBV reactivation in HbsAg positive rheumatoid arthritis patient. 2021.

Published

2024-01-01

How to Cite

1.
Wahyudi A, Fadrian, Afriant R. Warm Autoimmune Hemolytic Anemia with Chronic Hepatitis B. Sumat. Med. J. [Internet]. 2024Jan.1 [cited 2024Dec.22];7(1):47-50. Available from: https://talenta.usu.ac.id/smj/article/view/11836